TNYA

+ Watchlist + Portfolio

Tenaya Therapeutics, Inc.

Regulated industry Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.57
52-Week Range: $0.53 – $2.35
Market Cap: $126.49M
P/E (TTM): —
EPS (TTM): -0.52
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.15
PEG Ratio: —
Return on Equity: -121.86%
Return on Assets: -47.91%
Gross Margin: 100.00%
Operating Margin: -1882.79%
Profit Margin: 0.00%
Current Ratio: 4.52
Debt/Equity: 0.06
Total Debt: $3.95M
Free Cash Flow: $-32.60M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $52.35M

TNYA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$94.54M	$98.04M	$86.74M	$68.61M
Selling, General & Admin	$31.08M	$33.16M	$29.21M	$24.72M
Operating Expenses	$125.62M	$131.19M	$115.95M	$93.33M
Operating Income	-$125.62M	-$131.19M	-$115.95M	-$93.33M
EBITDA	-$119.15M	-$122.51M	-$107.48M	-$84.89M
Pretax Income	-$123.67M	-$124.08M	-$111.13M	-$90.60M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$123.67M	-$124.08M	-$111.13M	-$90.60M
Diluted EPS	-2.76	-1.68	-1.31	-0.59
Diluted Shares	44.82M	73.79M	84.82M	152.97M

TNYA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$95.27M	$45.68M	$4.32M	$100.55M
Receivables	$2.25M	$0.00	—	—
Current Assets	$193.75M	$111.58M	$67.38M	$105.59M
Total Assets	$278.94M	$170.51M	$119.94M	$146.92M
Current Liabilities	$24.25M	$22.73M	$15.97M	$15.44M
Total Debt	$15.10M	$12.42M	$13.61M	$10.83M
Total Liabilities	$35.57M	$31.09M	$27.09M	$23.66M
Retained Earnings	-$279.20M	-$403.28M	-$514.41M	-$605.01M
Shareholders' Equity	$243.38M	$139.42M	$92.85M	$123.27M
Working Capital	$169.51M	$88.85M	$51.40M	$90.15M

TNYA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$104.42M	-$102.07M	-$90.50M	-$68.26M
Capital Expenditure	-$20.63M	-$1.24M	-$1.02M	-$618.00K
Free Cash Flow	-$125.05M	-$103.31M	-$91.53M	-$68.88M
Depreciation & Amortisation	$6.47M	$8.69M	$8.47M	$8.44M
Stock-Based Compensation	$11.47M	$15.31M	$16.50M	$13.05M
Investing Cash Flow	$83.65M	$48.72M	$1.13M	$56.08M
Financing Cash Flow	$77.77M	$4.05M	$47.75M	$108.41M
Share Repurchases	$0.00	—	—	—
Net Change in Cash	$56.99M	-$49.31M	-$41.62M	$96.22M

TNYA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$225.00K	$1.11M
Research & Development	$21.08M	$17.37M	$15.36M	$14.80M	$14.84M	$16.60M
Selling, General & Admin	$6.46M	$6.71M	$5.57M	$5.98M	$5.45M	$5.41M
Operating Expenses	$27.54M	$24.08M	$20.94M	$20.77M	$20.29M	$22.01M
Operating Income	-$27.54M	-$24.08M	-$20.94M	-$20.77M	-$20.07M	-$20.90M
EBITDA	-$24.88M	-$22.00M	-$19.07M	-$18.95M	-$18.30M	-$19.20M
Pretax Income	-$26.86M	-$23.28M	-$20.27M	-$20.18M	-$19.27M	-$43.39M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$26.86M	-$23.28M	-$20.27M	-$20.18M	-$19.27M	-$43.39M
Diluted EPS	-0.24	-0.14	-0.12	-0.12	-0.09	-0.20
Diluted Shares	109.87M	162.79M	163.35M	175.05M	216.88M	217.57M

TNYA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$53.77M	$62.67M	$56.31M	$100.55M	$80.89M	$78.08M
Receivables	—	—	—	—	$10.63M	$371.00K
Current Assets	$94.48M	$75.88M	$61.24M	$105.59M	$96.56M	$86.01M
Total Assets	$143.95M	$122.15M	$104.98M	$146.92M	$135.07M	$93.54M
Current Liabilities	$14.15M	$12.65M	$13.21M	$15.44M	$16.78M	$19.02M
Total Debt	$12.91M	$12.21M	$11.53M	$10.83M	$10.12M	$3.95M
Total Liabilities	$24.56M	$22.32M	$22.11M	$23.66M	$28.88M	$24.13M
Retained Earnings	-$541.27M	-$564.56M	-$584.83M	-$605.01M	-$624.28M	-$667.67M
Shareholders' Equity	$119.40M	$99.83M	$82.87M	$123.27M	$106.19M	$69.41M
Working Capital	$80.33M	$63.22M	$48.03M	$90.15M	$79.78M	$66.99M

TNYA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$23.11M	-$15.61M	-$15.60M	-$13.94M	-$19.23M	-$3.55M
Capital Expenditure	-$383.00K	-$142.00K	-$26.00K	-$67.00K	-$11.00K	-$159.00K
Free Cash Flow	-$23.50M	-$15.76M	-$15.63M	-$14.01M	-$19.25M	-$3.71M
Depreciation & Amortisation	$2.66M	$2.08M	$1.86M	$1.83M	$1.76M	$1.70M
Stock-Based Compensation	$3.73M	$3.64M	$2.93M	$2.75M	$2.20M	$1.70M
Investing Cash Flow	$22.30M	$24.99M	$8.86M	-$67.00K	-$11.00K	-$159.00K
Financing Cash Flow	$50.26M	-$476.00K	$380.00K	$58.24M	-$415.00K	$909.00K
Net Change in Cash	$49.45M	$8.90M	-$6.36M	$44.23M	-$19.66M	-$2.80M

Market Snapshot

About

Tenaya Therapeutics is a biotechnology company focused on discovering, developing, and delivering curative therapies for heart disease. The company utilizes three distinct therapeutic platforms: gene therapy, cellular regeneration, and precision medicine approaches to address genetic and non-genetic forms of heart failure. Tenaya aims to transform the treatment landscape for patients with serious cardiovascular conditions.